• Vaccine Name: Influenza virus DNA vaccine H5 DNA
• Target Pathogen: Influenza virus
• Target Disease: Influenza (flu)
• Vaccine Ontology ID: VO_0004311
• Type: DNA vaccine
• Status: Research
• Host Species as Laboratory Animal Model: Human
• HA gene engineering:
  • Type: DNA vaccine construction
  • Description: Vector VRC-9123 expressed HA (Ledgerwood et al., 2011).
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid:
  • DNA vaccine plasmid name:
  • DNA vaccine plasmid VO ID: VO_0005005
• Immunization Route: Intramuscular injection (i.m.)

Human Response

• Vaccination Protocol: DNA vaccine encoding H5 as a priming vaccine (prime) followed by an H5N1 monovalent inactivated vaccine (MIV; boost) (Ledgerwood et al., 2011).
• Vaccine Immune Response Type: VO_0000286
• Immune Response: In the two studies, DNA priming with a 24-week monovalent inactivated vaccine (MIV) boost interval induced protective HAI titres in 21 (81%) of 26 of individuals, with an increase in geometric mean titre (GMT) of more than four times that of individuals given the MIV-MIV regimen at 4 or 24 weeks (GMT 103-206 vs GMT 27-33). Additionally, neutralising antibodies directed to the conserved stem region of H5 were induced by this prime-boost regimen in several individuals (Ledgerwood et al., 2011).
• Efficacy: DNA priming 24 weeks in advance of influenza vaccine boosting increased the magnitude of protective antibody responses (HAI) and in some cases induced haemagglutinin-stem-specific neutralising antibodies. A DNA-MIV vaccine regimen could enhance the efficacy of H5 or other influenza vaccines and shows that anti-stem antibodies can be elicited by vaccination in man (Ledgerwood et al., 2011).